91爆料

NIAID Applicant Assistance Program (AAP) Cycle Three Informational Webinar

for the NIAID Applicant Assistance Program (AAP) Cycle Three Informational Webinar on Tuesday May 25, 2021 at 2:00 p.m. EDT. This webinar will provide an introduction for the NIAID SBIR/STTR AAP program and the eligibility criteria. You will also have an opportunity to learn about the scope of one-on-one assistance, tips that can help maximize your benefits from the program, and online resources provided by AAP to support your grant submission.

NIAID Applicant Assistance Program- Cycle Three Opens Soon

The National Institute of Allergy and Infectious Diseases (NIAID) Applicant Assistance Program (AAP) Cycle Three will open for your applications on June 1, 2021. This cycle of the program is for the SBIR/STTR September 5, 2021 deadline. The online application link will be distributed through this mailing list before the application opens. We recommend that you plan to apply for the AAP in advance since this program typically fills quickly.

This program provides no cost support for companies planning to apply for a Phase II, Fast Track SBIR/STTR Award, or Direct-to-Phase II SBIR award. NIAID encourages participation from small businesses that are owned or operated by individuals who are traditionally underrepresented in biomedical sciences, such as women-owned small businesses, socially/economically disadvantaged small businesses, and companies located within Historically Under-utilized Business () Zones.

Participants in the AAP will work one-on-one with a Senior Consultant from Foresight Science & Technology, who will help you prepare your proposal with services such as: Outlines and Checklist, Market data for Commercialization Plan, Review and Feedback on Commercialization Plan, Research Strategy, Budget, or Attachments.

To be eligible for the program, you must meet the following criteria:

• The research area of interest aligns with the mission of NIAID. You can read to help you determine if your application aligns with the mission of NIAID.
• The company intends to submit application for the September 5, 2021 deadline.
• The company intends to submit a Phase II, Fast Track SBIR/STTR application, or Direct-to-Phase II SBIR application. (Completion of the is strongly recommended for all applicants)
• Phase II applicants must be within the following the expiration of the Phase I budget period.
• The company must be eligible to apply for NIH SBIR/STTR grants based on the .

If you meet these eligibility requirements and plan to apply for this program, stay tuned to this mailing list for the link to the online application form. Participation is limited to the first 25 qualified applicants.

Each company may submit only one application to the AAP.

For questions regarding the Applicant Assistance Program, please contact:
Mrs. Kelli Cardoso
Program Administrator
Foresight Science & Technology
Email: kelli.cardoso@foresightst.com

 

Seattle, WA (May 18, 2021)鈥擳he Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH) is pleased to announce investments in three new awards to expedite early-stage product development for promising biomedical innovations. The three awards are intended to reduce skin injury from wound dressing, to treat COVID-19 induced viral sepsis, and to treat kidney disease.

We congratulate the following recipients of the awards and their teams:

Eric Seibel, PhD and his multidisciplinary team from 91爆料 and Seattle Children鈥檚 Hospital is re-inventing high adhesion medical tape with UnTape. The goal is to reduce Medical Adhesive-Related Skin Injury (MARSI) without compromising on secure attachment to the skin, until it is time for rapid, painless removal.

George Ueda, PhD and James Lazarovits, PhD plan to develop a new class of therapeutic protein-based nanoparticles. WE-REACH will fund the first application of this platform technology to regenerate the cells lining blood vessels, which break down during severe infection and lead to lethal conditions such as acute respiratory distress syndrome and sepsis. With limited treatment options available, there is a major need for targeted therapies that treat COVID-19 and other infectious diseases.

Benjamin Freedman, PhD and the MiniKidney聽team plan to develop a novel therapeutic strategy for polycystic kidney disease, which affects millions and has no known cure. With this award they will utilize human mini-organs, that re-create the disease in a petri dish, to rapidly advance lead compounds into the clinic.

All three projects have received invaluable input from experts at the NIH, Food and Drug Administration, the Centers for Medicare & Medicaid Services, third-party payers, and the United States Patent and Trademark Office, as well as an entrepreneurial committee of local experts in the Seattle area.

The next round of WE-REACH projects will begin in Fall 2021.

###

WE-REACH is an NIH-designated entrepreneurial product innovation hub for the Pacific Northwest. WE-REACH is supported by public-private partnerships accelerating the transformation of biomedical discoveries into innovative products intended to improve patient care, access, and health. Learn more at /we-reach/.

Partners and contributors to WE-REACH include:

In addition to providing funding, CoMotion helps with sourcing, selecting, and ongoing guidance of the project teams. CoMotion partners with the 91爆料 community on their innovation journey, providing tools, connections, and acumen to transform ideas into economic and societal impact. Learn more at .

The Institute of Translational Health Sciences (ITHS) is dedicated to speeding scientific discovery to clinical practice for the benefit of communities throughout Washington, Wyoming, Alaska, Montana, Idaho and beyond. ITHS promotes this mission by fostering innovative research, cultivating multi-disciplinary research partnerships, and ensuring a pipeline of next generation researchers through educational and career development programs. Learn more at聽.

The Institute for Protein Design at the 91爆料 School of Medicine is creating a new world of synthetic proteins to address 21st-century challenges in medicine, energy, and technology. Learn more about our research at .

The 91爆料 School of Pharmacy: .

WE-REACH is supported by NIH Grant 1 U01 HL152401-01.